These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 18096566)

  • 21. Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation.
    Anderson K; Jacobson JS; Heitjan DF; Zivin JG; Hershman D; Neugut AI; Grann VR
    Ann Intern Med; 2006 Mar; 144(6):397-406. PubMed ID: 16549852
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A BRCA1/2 mutation, high breast density and prominent pushing margins of a tumor independently contribute to a frequent false-negative mammography.
    Tilanus-Linthorst M; Verhoog L; Obdeijn IM; Bartels K; Menke-Pluymers M; Eggermont A; Klijn J; Meijers-Heijboer H; van der Kwast T; Brekelmans C
    Int J Cancer; 2002 Nov; 102(1):91-5. PubMed ID: 12353239
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High rate of occult cancer found in prophylactic mastectomy specimens despite thorough presurgical assessment with MRI and ultrasound: findings from the Hereditary Breast and Ovarian Cancer Registration 2016 in Japan.
    Yamauchi H; Okawa M; Yokoyama S; Nakagawa C; Yoshida R; Suzuki K; Nakamura S; Arai M
    Breast Cancer Res Treat; 2018 Dec; 172(3):679-687. PubMed ID: 30203341
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is screening with magnetic resonance imaging in BRCA mutation carriers a safe and effective alternative to prophylactic mastectomy?
    Burness ML; Olopade OI
    J Clin Oncol; 2011 May; 29(13):1652-4. PubMed ID: 21444875
    [No Abstract]   [Full Text] [Related]  

  • 25. Breast magnetic resonance image screening and ductal lavage in women at high genetic risk for breast carcinoma.
    Hartman AR; Daniel BL; Kurian AW; Mills MA; Nowels KW; Dirbas FM; Kingham KE; Chun NM; Herfkens RJ; Ford JM; Plevritis SK
    Cancer; 2004 Feb; 100(3):479-89. PubMed ID: 14745863
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prophylactic and therapeutic mastectomy in BRCA mutation carriers: can the nipple be preserved?
    Reynolds C; Davidson JA; Lindor NM; Glazebrook KN; Jakub JW; Degnim AC; Sandhu NP; Walsh MF; Hartmann LC; Boughey JC
    Ann Surg Oncol; 2011 Oct; 18(11):3102-9. PubMed ID: 21947588
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging.
    Plevritis SK; Kurian AW; Sigal BM; Daniel BL; Ikeda DM; Stockdale FE; Garber AM
    JAMA; 2006 May; 295(20):2374-84. PubMed ID: 16720823
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MRI screening in a clinic population with a family history of breast cancer.
    Yu J; Park A; Morris E; Liberman L; Borgen PI; King TA
    Ann Surg Oncol; 2008 Feb; 15(2):452-61. PubMed ID: 18026801
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prophylaxis and screening options: recommendations for young women with BRCA mutations.
    Samuel JC; Ollila DW
    Breast Dis; 2005-2006; 23():31-5. PubMed ID: 16823164
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Breast cancer risk perception among women who have undergone prophylactic bilateral mastectomy.
    Metcalfe KA; Narod SA
    J Natl Cancer Inst; 2002 Oct; 94(20):1564-9. PubMed ID: 12381709
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term results of screening with magnetic resonance imaging in women with BRCA mutations.
    Passaperuma K; Warner E; Causer PA; Hill KA; Messner S; Wong JW; Jong RA; Wright FC; Yaffe MJ; Ramsay EA; Balasingham S; Verity L; Eisen A; Curpen B; Shumak R; Plewes DB; Narod SA
    Br J Cancer; 2012 Jun; 107(1):24-30. PubMed ID: 22588560
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expectations of Surveillance for Non-BRCA Gene Mutation Carriers at Increased Risk for Breast Cancer.
    Caskey R; Singletary B; Ayre K; Parker C; Krontiras H; Lancaster RB
    J Surg Res; 2020 Dec; 256():267-271. PubMed ID: 32712440
    [TBL] [Abstract][Full Text] [Related]  

  • 33. International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation.
    Metcalfe K; Eisen A; Senter L; Armel S; Bordeleau L; Meschino WS; Pal T; Lynch HT; Tung NM; Kwong A; Ainsworth P; Karlan B; Moller P; Eng C; Weitzel JN; Sun P; Lubinski J; Narod SA;
    Br J Cancer; 2019 Jul; 121(1):15-21. PubMed ID: 30971774
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.
    Meijers-Heijboer H; Brekelmans CT; Menke-Pluymers M; Seynaeve C; Baalbergen A; Burger C; Crepin E; van den Ouweland AW; van Geel B; Klijn JG
    J Clin Oncol; 2003 May; 21(9):1675-81. PubMed ID: 12721241
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of family history on choosing risk-reducing surgery among BRCA mutation carriers.
    Singh K; Lester J; Karlan B; Bresee C; Geva T; Gordon O
    Am J Obstet Gynecol; 2013 Apr; 208(4):329.e1-6. PubMed ID: 23333547
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers.
    Friebel TM; Domchek SM; Neuhausen SL; Wagner T; Evans DG; Isaacs C; Garber JE; Daly MB; Eeles R; Matloff E; Tomlinson G; Lynch HT; Tung N; Blum JL; Weitzel J; Rubinstein WS; Ganz PA; Couch F; Rebbeck TR
    Clin Breast Cancer; 2007 Dec; 7(11):875-82. PubMed ID: 18269778
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preventing breast, ovarian cancer in BRCA carriers: rational of prophylactic surgery and promises of surveillance.
    Agnantis NJ; Paraskevaidis E; Roukos D
    Ann Surg Oncol; 2004 Dec; 11(12):1030-4. PubMed ID: 15545500
    [No Abstract]   [Full Text] [Related]  

  • 38. Genetic Diagnosis before Surgery has an Impact on Surgical Decision in BRCA Mutation Carriers with Breast Cancer.
    Park S; Lee JE; Ryu JM; Kim I; Bae SY; Lee SK; Yu J; Kim SW; Nam SJ
    World J Surg; 2018 May; 42(5):1384-1390. PubMed ID: 29147896
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group.
    Metcalfe KA; Lubinski J; Ghadirian P; Lynch H; Kim-Sing C; Friedman E; Foulkes WD; Domchek S; Ainsworth P; Isaacs C; Tung N; Gronwald J; Cummings S; Wagner T; Manoukian S; Møller P; Weitzel J; Sun P; Narod SA;
    J Clin Oncol; 2008 Mar; 26(7):1093-7. PubMed ID: 18195327
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Survival of patients with BRCA1-associated breast cancer diagnosed in an MRI-based surveillance program.
    Møller P; Stormorken A; Jonsrud C; Holmen MM; Hagen AI; Clark N; Vabø A; Sun P; Narod SA; Mæhle L
    Breast Cancer Res Treat; 2013 May; 139(1):155-61. PubMed ID: 23615785
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.